Biomemory launches DNA Shield for offline data protection

Biomemory has launched DNA Shield, a cybersecurity service that stores sensitive digital information offline in synthetic DNA. It is the first commercial product built on the company's molecular IT platform.

The service is aimed at organisations seeking an additional layer of protection for critical data, including cryptographic keys, proprietary industrial information, regulated records and long-term institutional archives. Customers select and encrypt the material before it is encoded into synthetic DNA and held offline under managed custody.

Recovery is not intended for routine access. Instead, retrieval follows a controlled process triggered only when needed.

The product marks Biomemory's move into what it calls sovereign data protection, in which information is kept at rest away from network-connected systems and outside the active control plane. The approach is intended to reduce exposure to cyberattacks and preserve access to information over years or decades.

Use cases

Initial uses include continuity for cryptographic key custody, preservation of industrial intellectual property, maintenance of tamper-evident regulatory records and storage of what Biomemory describes as sovereign memory or golden records. The service is intended to complement existing tools such as hardware security modules, rather than replace them.

The launch follows a period of change for the business. Earlier this year, Biomemory acquired the assets of Boston-based Catalog Technologies, a company focused on DNA data storage and computing. The deal added research and production operations in Boston to Biomemory's base in Paris and expanded its intellectual property portfolio.

Leadership also changed during the year with the appointment of Laurent Guengant as Chief Executive Officer. Biomemory said the hire reflected a shift from research towards industrialisation and commercial deployment.

"DNA Shield is the moment Biomemory moves from proving a science to delivering a commercial product," said Laurent Guengant, Chief Executive Officer of Biomemory.

"Organisations need a way to hold their most critical digital assets, cryptographic keys, core intellectual property, regulated records, and long-term institutional memory, somewhere no single vendor, cloud, or system can reach, and to prove it still works over time. That is what DNA Shield is built for, and it is the first step on a roadmap that takes Biomemory from sovereign data protection today into storage, molecular search and compute."

Biomemory has opened an Early Access Program for organisations interested in the service. It did not disclose pricing or the number of early users.

The wider market for long-term data preservation has attracted interest as companies and public institutions confront growing concerns over ransomware, insider risk and the durability of digital systems over long periods. DNA-based storage has largely remained in research settings, with commercial adoption limited by cost, speed and operational complexity.

Biomemory is positioning DNA Shield as a managed service rather than a general-purpose storage platform. That narrows its initial scope to a small set of records organisations consider essential and irreplaceable, rather than large-scale everyday data archives.

Commercial shift

Vincent Franceschini, Vice President of Product Management at Biomemory and Co-Chair of the DNA Data Storage Alliance, said the launch represented a practical step beyond demonstration work.

"What changed this year is not just our product line. It is the shift from technology building blocks to a shipped product that customers can put to work," Franceschini said.

"DNA Shield is built on the same molecular platform we have spent years industrializing, but it is the first time we are asking a customer to rely on it operationally rather than as a research demonstration. Getting that right, end to end, from encoding to authorized recovery, is what makes us the first company bringing Molecular IT to market."